Who wins the combat, CAR or TCR?
Who wins the combat, CAR or TCR?
复制标题
DOI：
10.1038/s41375-023-01976-z
复制
发表时间：
2023-08
期刊：
影响因子：
11.4
通讯作者：
Kun Yun;Elizabeth L. Siegler;S. Kenderian
中科院分区：
文献类型：
--
作者：
Kun Yun;Elizabeth L. Siegler;S. Kenderian
嵌合抗原受体T（CAR-T）细胞疗法在过去几十年中因其在治疗B细胞恶性血液病方面的显著效果和突破而引起越来越多的关注。尽管CAR-T细胞疗法在临床上取得了显著的成功，但大多数接受治疗的患者在输注后仍会复发。汽车来源于T细胞受体（TCR）复合物和与T细胞活化相关的共刺激分子;然而，汽车和内源性TCR之间关于其敏感性、信号传导途径、杀伤机制和性能的相似性和差异性仍然没有完全理解。在这篇综述中，我们从各个方面讨论了汽车和TCR之间的平行比较，以及这些目前的发现如何提供新的见解并有助于提高CAR-T细胞治疗的疗效。
Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell hematological malignancies. Even though CAR-T cell therapy has outstanding clinical successes, most treated patients still relapse after infusion. CARs are derived from the T cell receptor (TCR) complex and co-stimulatory molecules associated with T cell activation; however, the similarities and differences between CARs and endogenous TCRs regarding their sensitivity, signaling pathway, killing mechanisms, and performance are still not fully understood. In this review, we discuss the parallel comparisons between CARs and TCRs from various aspects and how these current findings might provide novel insights and contribute to improvement of CAR-T cell therapy efficacy.